FIELD: organic chemistry, medicinal biochemistry, pharmacy.
SUBSTANCE: invention relates to substituted benzimidazoles of the formula (I): 
and/or their stereoisomeric forms, and/or their physiologically acceptable salts wherein one of substitutes R1, R2, R3 and R4 means a residue of the formula (II): 
wherein D means -C(O)-; R8 means hydrogen atom or (C1-C4)-alkyl; R9 means: 1. (C1-C6)-alkyl wherein alkyl is linear or branched and can be free of substituted by one-, bi- or tri-fold; Z means: 1. a residue of 5-14-membered aromatic system that comprises from 1 to 4 heteroatoms as members of the cycle that represent nitrogen and oxygen atoms wherein aromatic system is free or substituted; 1.1 a heterocycle taken among the group of oxadiazole or oxadiazolone that can be unsubstituted or substituted; 2. (C1-C6)-alkyl wherein alkyl is a linear or branched and monosubstituted with phenyl or group -OH; or 3. -C(O)-R10 wherein R10 means -O-R11, -N(R11)2 or morpholinyl; or R8 and R9 in common with nitrogen atom and carbon atom with that they are bound, respectively, form heterocycle of the formula (IIa): 
wherein D, Z and R10 have values given in the formula (II); A means a residue -CH2-; B means a residue -CH-; Y is absent or means a residue -CH2-; or X and Y in common form phenyl. The cyclic system formed by N, A, X, Y, B and carbon atom is unsubstituted or monosubstituted with (C1-C8)-alkyl wherein alkyl is monosubstituted with phenyl, and other substitutes R1, R2, R3 and R4 mean independently of one another hydrogen atom, respectively; R5 means hydrogen atom; R6 means the heteroaromatic cyclic system with 5-14 members in cycle that comprises 1 or 2 nitrogen atoms and can be unsubstituted or substituted. Also, invention relates to a medicinal agent for inhibition of activity of IkB kinase based on these compounds and to a method for preparing the indicated agent. Invention provides preparing new compounds and medicinal agents based on thereof for aims for prophylaxis and treatment of diseases associated with the enhanced activity of NFkB.
EFFECT: valuable medicinal properties of compounds and composition.
4 cl, 7 tbl, 224 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING IkB KINASE INHIBITOR IN ANESTHETIZING TREATMENT | 2003 |
|
RU2320338C2 |
| SUBSTITUTED INDOLES | 2000 |
|
RU2255087C2 |
| DERIVATIVES OF INDOLE OR BENZIMIDAZOLE FOR MODULATION OF IkB KINASE | 2003 |
|
RU2318820C2 |
| DERIVATIVES OF BICYCLIC IMINOACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | 2004 |
|
RU2335494C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| UREA AND SULPHAMIDE DERIVATIVES AS TAFIA INHIBITORS | 2007 |
|
RU2459619C2 |
| SUBSTITUTED DIAMINOCARBOXYLIC ACIDS | 1998 |
|
RU2196768C2 |
| NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
| IMIDAZOLE DERIVATIVES AS TAFIa INHIBITORS | 2005 |
|
RU2375356C2 |
| SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | 2012 |
|
RU2621695C2 |
